AON — Aon plc

The tape is unambiguous as of 2026-09-13: -14.1% over one month, -6.31% over one week, price $0.25 off the 52-week low of $302.44, RSI at 28.73. The cause is specific and dated - the 2026-08-31 USI agreement for roughly $17 billion in cash, funded primarily with newly issued debt and senior notes, layered on top of $12.95B of long-term debt and only $9.66B of stockholders' equity at 2026-06-30. Sell-side reacted by trimming targets (Wells Fargo $419 to $383, BMO $375 to $360, Mizuho to $398), and the published consensus rating field reads 'Hold' with a 0 strong-buy / 18 buy / 19 hold / 1 sell breakdown. The stale consensus target of $393.30 (18 analysts) is not credible against post-deal targets clustered at $360-$398, but even the lower end implies upside the market is refusing to pay for until financing terms, synergies, and the deleveraging path are known. Underneath the deal noise, sentiment is also absorbing a genuine deceleration: Q2 2026 revenue grew just +2.2% YoY and Q2 free cash flow fell 34% YoY.

Decelerating, and deceleration is now the dominant fact. Revenue YoY: +26.0% (Q3 2024), +22.9% (Q4 2024), +16.2% (Q1 2025), +10.5% (Q2 2025), +7.4% (Q3 2025), +3.7% (Q4 2025), +6.4% (Q1 2026), +2.2% (Q2 2026, $4,246M vs $4,155M). The fat 2024-25 prints include NFP acquisition revenue rolling into comps, so underlying organic growth is lower and closer to the +2-4% now showing - this is a slowing trend, not a one-quarter blip. Operating margin is mixed rather than cleanly deteriorating: Q2 2026 operating income of $823M fell 4.2% YoY with margin compressing to 19.4% from 20.7%, while Q1 2026 margin expanded to 35.9% from 30.9%. That Q1/Q2 whipsaw looks like cost timing plus early deal/integration spend, but two quarters is not proof. Free cash flow is the yellow flag: H1 2026 of $846M vs H1 2025 of $816M is only +3.7%, and the mix worsened badly - Q2 2026 FCF of $483M was 34% below Q2 2025's $732M, only partly offset by an unusually weak Q1 2025 ($84M). Reported EPS needs care: TTM diluted EPS of $18.31 includes Q4 2025, where net income of $1,693M exceeded operating income of $1,337M - a large below-the-line gain or tax benefit - so underlying earnings power is meaningfully below the headline TTM number.

As of 2026-09-13, AON traded at 16.6x TTM EPS of $18.31 and 16.1x the $18.79 next-FY consensus EPS, against a 5-year average P/E of 30.1x, with P/S of 3.65x versus a 5-year average of 4.86x - the deterministic overlay correctly labels this 'Cheap vs. its own history' (score 90.5). PEG of 0.32 and EV/EBITDA of 12.65x also screen cheap versus brokerage peers, which normally trade high-teens to low-20s EV/EBITDA. Two honest caveats: (1) the headline P/E is flattered by the Q4 2025 one-off, so on cleaner earnings the multiple is closer to 19-20x; (2) some of the de-rating is justified, not mispricing, given ~2-4% organic growth and a balance sheet about to absorb ~$17B of new debt. Cheap on the numbers, but not the bargain the 16.6x headline implies.

The stock is pricing a stall, not a recovery. Consensus next-FY EPS of $18.79 is only +2.6% above TTM EPS of $18.31, which means the market has already marked Aon down from compounder to low-growth, and the 16.1x forward multiple bakes in skepticism about the USI deal's interest cost and integration. That creates an asymmetric setup in both directions: if Q3 2026 shows organic growth holding ~4-5% and management lays out a credible deleveraging/synergy path, the multiple re-rates toward the peer range and the current price looks like an over-punishment. If instead consensus next-FY EPS gets cut for the ~$850M of incremental pre-tax interest on $17B of new debt (before any USI EBITDA contribution) and organic growth slips below 3%, then today's 'cheap' 16x becomes a 19-20x on revised numbers and the stock is fairly valued or worse. Watch the Q3 2026 print for the interest-expense guide and synergy detail - that is the single swing factor in whether this is a value opportunity or a value trap.

As of 2026-09-13, RSI(14) was 28.73 - oversold - with price 10.11% below the 20-day SMA, 13.80% below the 50-day and 10.04% below the 200-day, alongside a -6.31% one-week and -14.10% one-month return. That is a downtrend with an oversold reading on top of it, not a range and not a bottom; oversold conditions driven by a fresh, unresolved fundamental catalyst (a $17B debt-funded deal) routinely persist for weeks. The timing implication is explicit: there is no technical case for catching this knife. The first constructive signals would be a reclaim of the 20-day SMA, RSI back above 40, and ideally simultaneous news on deal financing - until then, the path of least resistance remains lower toward the $302.44 52-week low.

• Cost of debt financing: the ~$17B USI consideration is funded primarily through newly issued debt and senior notes, so the pricing of that issuance and the post-inflation rate environment directly determine the deal's EPS math and Aon's interest coverage.
• Commercial P&C pricing cycle: rate increases are moderating or turning negative in parts of the market, which compresses commission growth in Commercial Risk even with flat exposure units - the primary organic-growth headwind and the reason reported growth is falling from the 2024-25 acquisition-boosted levels.
• Healthcare cost inflation (projected ~9.5% for 2027) supports demand for Health Solutions advisory and benefits work as clients seek to manage claims cost.
• Secular demand for specialty and analytics exposure - cyber, data-center and construction risk, supply-chain concentration - sustains long-run demand for Aon's advisory platforms even in a soft pricing cycle.
• Sector rotation and multiple sensitivity: brokerage valuations are quality- and rate-sensitive, and a de-rating regime penalizes leveraged M&A stories like Aon relative to organic compounders such as MMC and AJG, which pressures the relative multiple regardless of deal outcome.

• Q3 2026 earnings (expected late October 2026): the first real forum for USI financing cost, synergy targets, deleveraging schedule, and whether Q2's margin and free-cash-flow softness was a timing blip.
• Regulatory and antitrust clearance plus the closing timeline for the USI acquisition - any delay or remedy requirement is a direct negative.
• Pricing and terms of the senior notes and any incremental debt raised for the all-cash $17B consideration; issuance terms set the permanent interest burden.
• Management commentary at investor and industry conferences on capital allocation, buyback capacity and organic margin expansion.
• Direction of commercial P&C pricing into the January 2027 renewal season - stabilization supports organic growth, further softening pressures it.

• Leverage step-up: long-term debt of $12.95B and debt-to-equity of 1.64x at 2026-06-30 rise substantially with ~$17B of all-cash consideration against just $9.66B of stockholders' equity, driving higher interest expense and sharply limiting buyback and dividend growth capacity.
• Execution and integration risk on USI: building a U.S. middle-market platform means integrating people, producer relationships and technology, with real retention and dis-synergy risk over a multi-year period.
• Structural organic deceleration: reported growth has fallen from +16-26% YoY in 2024-25 to +2.2% in Q2 2026, and the P&C pricing tailwind that flattered prior years is fading - this looks structural rather than a temporary dip.
• Earnings quality and multiple risk: TTM EPS of $18.31 is inflated by a Q4 2025 quarter where net income ($1,693M) exceeded operating income ($1,337M); if consensus EPS of $18.79 is reset for the new interest burden, today's 'cheap' multiple re-rates higher fast.
• Free cash flow softness compounding the leverage story: Q2 2026 FCF of $483M was down 34% YoY versus $732M, so the cash flow needed to deleverage is shrinking at exactly the moment debt is rising.

Aon is a genuinely high-quality, capital-light intermediary - 83.1% gross margin, 22.3% net margin, 12.2% ROIC, 39.5% ROE, roughly $3.2B of TTM free cash flow - that has made its balance sheet the story. The 2026-08-31 announcement of a roughly $17B all-cash USI acquisition, funded with debt on top of an already $12.95B long-term debt load, knocked the stock to its 52-week low and compressed the forward P/E to 16.1x versus a 30.1x five-year average. At my calculated fair value near $338, the risk/reward has stopped being bad, but with organic growth at ~2-4%, Q2 free cash flow down 34% YoY and no technical bottom in sight, this is a 'prove it on the Q3 2026 print' situation rather than a buy today - existing holders can justify patience, new money should wait for financing detail and evidence the deceleration is a comps artifact rather than a new normal.

Forward-P/E method: applied a ~18x multiple to the $18.79 next-FY consensus EPS (which is 16.1x at the 2026-09-13 price of $302.69) = ~$338. The 18x is a deliberate discount to brokerage peers (~20-22x forward) and to Aon's own 5-year average P/E of 30.1x, reflecting ~3x post-deal leverage and ~2-4% organic growth, but a premium to the current 16.1x because a 5.1% TTM free-cash-flow yield on ~$3.25B of FCF from an 83%-gross-margin annuity business is being over-punished. Cross-checked on EV/EBITDA: 12.65x today on roughly $6.0B of EBITDA; 14x on ~$76B of enterprise value implies ~$341 per share, so both approaches converge in the $338-341 area.